Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
On Thursday, H.C. Wainwright analyst Emily Bodnar raised the price target on Femasys Inc. (NASDAQ:FEMY) shares to $15.00, up from the previous target of $12.00, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for FEMY range from $3.00 to $15.00, with the stock currently trading near $1.57. The company has shown strong momentum with a 42.73% return year-to-date. The adjustment follows Femasys’ announcement of a new partnership with CNY Fertility, a national provider of fertility services in the United States.
Femasys revealed that its FemaSeed product would be offered as an infertility treatment throughout CNY Fertility’s network, which spans 11 locations. These sites are not only situated on the East Coast but also in other states such as Colorado, Texas, California, and Florida. With a current market capitalization of $35.26 million and a healthy current ratio of 3.94, InvestingPro analysis indicates the company is well-positioned for expansion despite being in growth phase. CNY Fertility is known for a comprehensive range of fertility services, including in vitro fertilization (IVF), intrauterine insemination (IUI), and genetic testing. In 2022, the provider reported conducting over 7,300 IVF cycles.
This collaboration is significant as it introduces FemaSeed to states previously without access and enhances its availability in states with existing centers that may serve different client demographics. FemaSeed is now available in at least 53 centers across the U.S., a notable expansion since its launch in the second half of 2024, demonstrating a rapid market penetration.
Analysts at H.C. Wainwright underscore the potential for FemaSeed to generate additional revenue streams from 2025 onward as Femasys continues to increase the product’s presence and consumer awareness. FemaSeed is positioned as a user-friendly option that can be administered in-office without anesthesia or hormones, potentially serving as an alternative or precursor to more invasive procedures like IVF and intracytoplasmic sperm injection (ICSI).
The firm’s revenue projections for FemaSeed are $1.0 million in 2024, with expectations of a significant increase to $11 million in 2025. These projections align with InvestingPro data showing revenue growth of 15.33% in the last twelve months, though the company is currently operating at a negative EBITDA of $17.21 million. The continued growth and strategic partnerships reinforce the Buy rating and the elevated price target for Femasys stock. InvestingPro subscribers have access to 10 additional key insights about FEMY’s growth potential and financial health.
In other recent news, Femasys Inc. has received the CE mark certification for its FemBloc delivery system, marking the first global regulatory approval for this non-surgical contraceptive method under the European Union Medical (TASE:BLWV) Device Regulation. This certification allows Femasys to initiate pre-marketing activities in Europe, targeting key markets such as Spain, France, Italy, and Germany. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys, with a price target of $12, highlighting the faster-than-anticipated European approval as a positive development. Additionally, Femasys has secured UK regulatory approval for three of its products: FemaSeed, FemVue, and FemCerv, expanding its reach in the women’s health market. FemaSeed offers a novel approach to artificial insemination, while FemVue and FemCerv provide diagnostic solutions for fallopian tube evaluation and cervical cancer detection, respectively. The UK approval follows the products’ existing clearances in the US, Europe, Canada, and Israel. Femasys CEO Kathy Lee-Sepsick emphasized the company’s commitment to providing safe and effective options globally. Meanwhile, Femasys continues its FDA-approved pivotal clinical trial for FemBloc in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.